Selective targeting of the tumour vasculature.
Selective targeting of the tumour vasculature in the treatment of solid organ malignancies is an alternative to conventional chemotherapy treatment. As the tumour progressively increases in size, angiogenesis or the formation of new vasculature is essential to maintain the tumour's continual growth and survival. Therefore disrupting this angiogenic process or targeting the neovasculature can potentially hinder or prevent further tumour expansion. Many anti angiogenic agents have been investigated with many currently in clinical trials and exhibiting varied results. Vascular disrupting agents such as the Combretastatins and OXi 4503 have shown promising preclinical results and are currently being examined in clinical trials.
Chan
Lie S
LS
Department of Surgery, University of Melbourne, Austin Health, Melbourne, Victoria, Australia. l.chan11@pgrad.unimelb.edu.au
Daruwalla
Jurstine
J
Christophi
Christopher
C
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000517:prevention & control*
D020533:Angiogenesis Inhibitors